What Happened

The U.S. Food and Drug Administration (FDA) issued final guidance titled “Postapproval Pregnancy Safety Studies” on May 8, 2026, outlining recommended methods for studying drug and biologic safety when used in pregnancy. The guidance finalizes the draft issued in May 2019 and clarifies approaches sponsors and investigators can use after product approval, including pregnancy registries, analyses of real‑world data, and case series synthesis. It is intended to inform postmarket study design, data sources, and how to generate information suitable for labeling updates and clinician counseling. The guidance applies to products regulated by the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER) and will affect sponsors, regulators, and clinicians caring for pregnant patients [1] [2] [5].

Why It Matters

Pregnant patients are often exposed to medications despite limited human pregnancy data at initial approval, leaving prescribers without robust evidence for risk–benefit discussions; the FDA notes a frequent lack of meaningful human pregnancy data at marketing and urges better postapproval data collection to fill that gap [1] [8]. The guidance addresses that clinical problem by recommending multiple complementary study designs — pregnancy registries, observational analyses of electronic health records and claims, and structured case reports — to capture maternal, fetal, and neonatal outcomes and improve the evidence base for labeling. Because pregnancy exposures can have timing‑dependent effects on organogenesis and longer‑term neurodevelopmental outcomes, the guidance emphasizes study design elements and expert input from obstetrics, pediatrics, genetics, and biostatistics to detect safety signals and characterise risks. Sponsors of newly approved and marketed products, and clinicians who prescribe to pregnant patients, will see clearer expectations for postmarket data collection and pathways to update product information [1] [2] [5] [8].

What Changed

  • No standardised postapproval approach → The FDA now provides a menu of recommended methods (pregnancy registries, observational real‑world data studies, and descriptive case reports) with design features to improve data quality and interpretability. [2]
  • Draft 2019 guidance → Final guidance dated May 8, 2026, formally replaces the draft document and clarifies the agency’s current thinking for industry and investigators. [2]
  • Prior reliance on ad hoc reporting → New emphasis on preplanned pregnancy safety study protocols and collaboration with experts in obstetrics, pediatrics, genetics, and statistics to reduce bias and improve outcome ascertainment. [1]
  • Single data source reliance → Recommendation to use complementary data sources (registry plus real‑world databases or targeted cohorts) to strengthen causal inference and support labeling changes. [2]
  • Limited outcome definitions → Guidance specifies maternal, fetal, neonatal, and longer‑term neurodevelopmental endpoints and recommends standardised definitions and follow‑up intervals to improve comparability across studies. [5]
  • Unclear pathway to labeling updates → The guidance describes how postapproval pregnancy safety data can be used to inform labeling changes and the types of evidence the FDA will consider for those updates. [1]
  • Minimal pharmacokinetic focus → Guidance points sponsors to existing FDA documents on pharmacokinetics in pregnancy for dosing considerations and to integrate PK/PD studies where relevant to safety assessments. [2] [5]

What This Means for Your Practice

Obstetricians, maternal‑fetal medicine specialists, primary care clinicians, and pharmacists in outpatient and hospital settings may see more systematic postmarket data about drugs their pregnant patients use, and they will be asked more often to enrol patients in pregnancy registries or to document exposures and outcomes in standardised ways; this will change how patient counseling, documentation, and follow‑up are organised in clinic workflows. Practices that prescribe drugs with limited pregnancy data should identify which products have active registries or ongoing observational studies, update consent and documentation templates to capture exposure timing and outcome data, and coordinate with pharmacy and specialty colleagues to notify sponsors when appropriate. Electronic health record teams should prepare to support structured data capture for pregnancy exposures and outcomes that align with FDA recommendations so analyses of real‑world data are feasible. As these elements are implemented, how will individual practices balance the time required for enhanced documentation and patient enrolment with routine clinical demands while ensuring high‑quality follow‑up for infants and mothers?

Sources and Further Reading

[1] US Food and Drug Administration. FDA Issues Guidance to Improve Collection of Pregnancy Safety Data for Drugs and Biologics. May 08, 2026. URL: https://www.fda.gov/news-events/press-announcements/fda-issues-guidance-improve-collection-pregnancy-safety-data-drugs-and-biologics

[2] US Food and Drug Administration. Postapproval Pregnancy Safety Studies. May 2026. URL: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postapproval-pregnancy-safety-studies

[5] US Food and Drug Administration. Postapproval Pregnancy Safety Studies Guidance for Industry. May 2026. URL: https://www.fda.gov/media/124746/download

[8] US Food and Drug Administration. Division of Pediatrics and Maternal Health - Post-Approval Studies in Pregnant Individuals. Content current as of: 07/25/2024. URL: https://www.fda.gov/drugs/development-resources/division-pediatrics-and-maternal-health-post-approval-studies-pregnant-individuals